Skip to main content
Figure 2 | Molecular Cancer

Figure 2

From: Phenylbutyrate interferes with the Fanconi anemia and BRCA pathway and sensitizes head and neck cancer cells to cisplatin

Figure 2

Phenylbutyrate abrogates the formation of FANCD2 foci following cisplatin treatment. (A) UM-SCC-6 cells were treated with 2 mM phenylbutyrate (PB) for 48 hours before adding 5 μM cisplatin and incubated for an additional 24 hours. Cells were then fixed and stained with anti-FANCD2 antibodies and the DNA dye DAPI. (B) The three head and neck cancer cell lines were treated as in (A) and FANCD2 foci were counted in a blind fashion using a fluorescence microscope. Cells containing more than 20 FANCD2 foci are expressed as a percentage of 100 cells analyzed for each condition and cell line. Error bars represents the standard error of the mean from three independent experiments. Statistical analysis using the student's t-test shows that phenylbutyrate significantly reduced the number of cells with > 20 FANCD2 nuclear foci. p-values are indicated in the graph. Bars: light gray, UM-SCC-1; gray, UM-SCC-6; black, UM-SCC-25.

Back to article page